Form 4: Immunome Inc. Executive Max Rosett Reports Stock Option Grant
SEC Form 4 Filing
EVP, Operations & CFO of Immunome, Max Rosett, reports the acquisition of stock options.
Summary
- On May 16, 2024, Max Rosett, EVP, Operations & CFO of Immunome Inc., reported the acquisition of stock options.
- The stock option grants the right to buy 30,000 shares of Immunome Inc. common stock at an exercise price of $14.40.
- 25% of the shares subject to the options vest on May 16, 2025, and the remaining shares vest monthly over the following 36 months.
- The options expire on May 15, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding stock option grants, which is neutral in sentiment.
Positives
- The grant of stock options to a key executive aligns their interests with those of the shareholders.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of management's confidence in the company's future prospects.
Stakeholder Impact
- The stock option grant could incentivize the executive to improve company performance, benefiting shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/16/2024 | Date of transaction: Stock option grant to Max Rosett. |
| 05/16/2025 | 25% of the shares subject to the options vest. |
| 05/15/2034 | Expiration date of the stock options. |
| 05/17/2024 | Date of signature of the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.